
样式: 排序: IF: - GO 导出 标记为已读
-
Promise and pitfalls of liver xenotransplantation Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-06-19 Burcin Ekser, Luis A. Fernandez
-
The oesophagus as an immune organ Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-06-18 Mark Rochman, Kendall Kellerman, Michael P. Jankowski, Marc E. Rothenberg
-
The IDEAL framework for machine perfusion in liver transplantation Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-06-16 Otto B. van Leeuwen, David Nasralla, Carlo D. L. Ceresa, Philipp Dutkowski, Peter J. Friend, Gabriel C. Oniscu, Robert J. Porte, Vincent E. de Meijer
-
Post-antibiotics microbiome restoration driven by diet Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-06-11 Jordan Hindson
Gut microbiome dysbiosis is associated with a wide range of diseases, but factors influencing restoration of the microbiome are less well-studied. In a study published in Nature, researchers tracked the recovery of the gut microbiome after antibiotic treatment in mice receiving either a regular chow diet or a high-fat, low-fibre ‘Western’ diet. The mice on the regular chow diet (high in fibre) exhibited
-
Head-to-head trial of HCV treatment regimens Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-06-11 Jordan Hindson
A head-to-head trial published in The Lancet has compared two antiviral combination regimens for treatment of chronic hepatitis C virus (HCV) infection. The randomized controlled non-inferiority trial (ISRCTN, 61522291), conducted in two public hospitals in Vietnam, randomized adults (n = 624) with chronic HCV infection to receive 400 mg sofosbuvir and either 60 mg daclatasvir or 100 mg velpatasvir
-
EASL Congress 2025 Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-06-06 Eleni Kotsiliti
In May 2025, Nature Reviews Gastroenterology & Hepatology attended in person the European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam, The Netherlands. This was the fourth year the international liver conference was in person and virtual, with the session recordings available to delegates for 3 months. According to the organizers, 7,742 people from 119 countries attended
-
The gut microbiome connects nutrition and human health Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-06-04 Yolanda Sanz, John F. Cryan, Mélanie Deschasaux-Tanguy, Eran Elinav, Rebekka Lambrecht, Patrick Veiga
-
Public health policies to prevent alcohol-related liver disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-06-04 Richard Parker, Juan P. Arab, Jeffrey V. Lazarus, Ramon Bataller, Ashwani K. Singal
-
Prioritizing inflammatory bowel disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-06-02
Inflammatory bowel disease remains a global health challenge, despite advances in treatment and understanding of disease biology. In this issue, we focus on the most pressing priorities in inflammatory bowel disease research and care.
-
SSRIs and depression: role of gut–brain communication Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-23 Lin Y. Hung
The development of antidepressant drugs was largely based on the notion that a deficiency of monoaminergic function, specifically noradrenaline, was thought to contribute to depression. The first-generation antidepressant drugs, tricyclic antidepressants and monoamine oxidase inhibitors, were therefore developed to inhibit either monoamine reuptake or its degradation, respectively. Although both drug
-
Redefining cancer care: the case for an onco-gastroenterology subspecialty Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-23 Rashid Lui, Renu Dhanasekaran, Yu Bin Tan, Claudia Wing-Kwan Wu, Jan Bornschein, Daniel Q. Huang, Arndt Vogel, Shilpa Grover
-
Bridging the gap: increasing MENA representation in MASLD clinical trials Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-23 Mohamed El-Kassas
Despite the Middle East and North Africa having the highest global burden of metabolic dysfunction-associated steatotic liver disease, patients from this region remain markedly under-represented in the disease clinical drug trials. Addressing this gap is essential for ensuring equitable access to novel therapies and enhancing global liver health.
-
Menopause and gastrointestinal health and disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-23 Dana Ley, Sumona Saha
-
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-22 Deiziane V. S. Costa, Beatriz Thomasi, Gerly A. C. Brito, Brian D. Gulbransen, Cirle A. Warren
-
Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-22 Robert F. Schwabe, David A. Brenner
-
Digestive Disease Week 2025 Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-14 Katrina Ray
From 3–6 May 2025, Nature Reviews Gastroenterology & Hepatology attended Digestive Disease Week in San Diego, USA. According to the organizers, more than 13,400 people were registered for the conference (in-person and online). As usual, a wide array of sessions was available across basic, translational and clinical science in gastroenterology and hepatology with tantalizing insights into unpublished
-
Early Crohn’s disease: can we change the disease course? Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-14 Geert D’Haens, Melek Simsek
Current treatments for Crohn’s disease prioritize early intervention with biological therapies, with several landmark trials demonstrating that starting biologic agents within the first years of diagnosis leads to superior patient outcomes. Although challenges remain, early use of biological treatments is increasingly supported in managing moderate to severe Crohn’s disease.
-
Inflammatory bowel disease: classifying global regions by epidemiological stage Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-13 Jordan Hindson
It has previously been proposed that the epidemiology of inflammatory bowel disease (IBD) in a region evolves predictably across four distinct epidemiological stages determined by changes in incidence and prevalence. The four stages are emergence, acceleration in incidence, compounding prevalence and prevalence equilibrium. Now, a new study published in Nature has applied this framework to real-world
-
Deep Visual Proteomics elucidates α1-antitrypsin deficiency Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-13 Jordan Hindson
In a new study published in Nature, researchers have investigated the progression of the genetic liver disease α1-antitrypsin deficiency (AATD) in human tissue. Spatial proteomics by mass spectrometry and machine learning, via a technique termed Deep Visual Proteomics, was able to analyse the progressive proteotoxicity of AATD, a condition that causes misfolding of α1-antitrypsin in hepatocytes. A
-
Gut-to-brain vagal afferents transmit reward signals Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-12 Kenny L. Chan
Although the gut–brain axis has long been thought to guide mood and behaviour, it had not been thoroughly investigated at a neurocircuit level until 2018, when a key paper by Han and colleagues delineated a gut-to-brain circuit stimulating reward behaviour. By mapping and manipulating the peripheral nervous system, the investigators found that sensory neurons in the nodose ganglion of the vagus nerve
-
Maintaining remission in ulcerative colitis Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-01 Eleni Kotsiliti
A new clinical study published in The Lancet Gastroenterology & Hepatology assessed the effectiveness of laparoscopic appendicectomy in maintaining remission in ulcerative colitis. From 2012 to 2022, 1,386 patients with ulcerative colitis in remission were initially screened in a pragmatic, open-label, randomized controlled superiority trial (ACCURE) in 22 centres across the Netherlands, Ireland and
-
Congenital diarrhoea and enteropathy genetics Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-01 Eleni Kotsiliti
Congenital diarrhoea and enteropathy (CODE) disorders are rare and primarily affect the intestinal epithelium in infancy, leading to substantial morbidity and mortality. In a new multicentre study published in The New England Journal of Medicine, investigators in Canada and the USA characterized the genetic profile of CODE disorders via next-generation sequencing and identified known and novel pathogenic
-
Developing microbiome research in Africa: the essential role of clinician scientists Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-30 Mashiko Setshedi, Gianluca Ianiro
We read with interest the Comment by Kouidhi and Oduaran, in which they advocate the standardization of microbiome data collection across Africa (Kouidhi, S. & Oduaran, O. H. Strengthening the foundation of African microbiome research: strategies for standardized data collection. Nat. Rev. Gastroenterol. Hepatol. 21, 742–743 (2024))1. They highlight the tremendous opportunities of African microbiome
-
Common misconceptions and controversies in the management of irritable bowel syndrome Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-25 Christopher J. Black, Carolina Olano, Eamonn M. M. Quigley, Alexander C. Ford
-
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-22 Virginia Solitano, Charles N. Bernstein, Iris Dotan, Axel Dignass, Rhondell Domilici, Marla C. Dubinsky, Richard B. Gearry, Ailsa Hart, Gilaad G. Kaplan, Christopher Ma, Fernando Magro, Joyce Wing Yan Mak, Siew C. Ng, Remo Panaccione, Sreecanth Raja, David T. Rubin, Corey A. Siegel, Vipul Jairath, Laurent Peyrin-Biroulet, Silvio Danese
-
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-14 Hinrich Abken
-
Diet-driven microbiome restoration associated with cardiometabolic benefits Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-10 Jordan Hindson
The effects of industrialization on the human gut microbiome have been associated with an increased risk of non-communicable diseases. In a new study published in Cell, researchers have investigated the effect of a non-industrialized-type diet on the gut microbiome and on the risk of chronic diseases. The researchers conducted a randomized controlled feeding trial in 30 healthy Canadian adults. Participants
-
Metabolic diseases in the East Asian populations Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-08 Zhonghan Sun, Yan Zheng
-
A sensory neuron–gastric cancer circuit Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-04 Eleni Kotsiliti
A new study published in Nature explored the role of sensory nerves in gastric cancer. “Cancer cells in extra-cranial solid tumours create an electrical circuit with the sensory nervous system,” says Timothy Wang, corresponding author of the study. Using multiple mouse models of gastric cancer, the researchers showed that sensory nerves expressing calcitonin gene-related peptide (CGRP) created a neural
-
Behavioural interventions increase uptake of CRC screening Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-04 Katrina Ray
A new trial, published in The Lancet, has shown that adding a single sentence with a suggested deadline for return of a faecal immunochemical test (FIT) in the invitation letter reduced the need to issue reminder letters and led to a more timely FIT return as part of a national colorectal cancer (CRC) screening programme. The TEMPO trial was a 2 × 4 factorial, eight-arm, randomized controlled trial
-
International collaborative research to improve gallbladder cancer prevention Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-04 Dominique Scherer, Rajiv Kumar, Justo Lorenzo Bermejo
-
Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-24 Bossng Kang
I read with great interest the article by Lee et al. (Lee, B. P. et al. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement. Nat. Rev. Gastroenterol. Hepatol. 21, 626–645 (2024))1. In their Consensus Statement1, the authors are to be commended for their comprehensive framework, which integrates methodologies from alcohol use disorder
-
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’ Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-24 Mack C. Mitchell, Brian P. Lee, Jessica Mellinger, Laura E. Nagy
We thank Kang for their comments on our recent Consensus Statement (Lee, B. P. et al. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement. Nat. Rev. Gastroenterol. Hepatol. 21, 626–645 (2024))1 to incorporate genetic variations into consideration (Kang, B. Incorporating genetic variations in alcohol-associated liver disease trials
-
Cell therapy for liver disorders: past, present and future Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-18 M. Carmen Ortuño-Costela, Massimo Pinzani, Ludovic Vallier
-
EASL Liver Cancer Summit 2025 Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-12 Jordan Hindson
From 20–22 February 2025, Nature Reviews Gastroenterology & Hepatology attended in person the European Association for the Study of the Liver (EASL) Liver Cancer Summit 2025 in Paris, France. The meeting was attended by 720 delegates from 51 countries and there were 238 abstracts submitted, according to the organizers.
-
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-07 Katrina Ray
Vaccines to treat cancer are currently in development, with the potential for personalized treatments targeting specific mutations in various cancer types. A previous phase I trial reported that a personalized RNA neoantigen vaccine was safe and stimulated anti-tumour CD8+ T cells in patients with pancreatic cancer that correlated with delayed recurrence of pancreatic adenocarcinoma (8 of 16, at 1
-
Estimating dietary intake from human stool DNA Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-07 Katrina Ray
Accurately determining dietary and nutrient intake in nutrition research is challenging, and usually reliant on self-reported methods such as dietary questionnaires that can introduce bias. A new study published in Nature Metabolism reports a method for quantifying food-derived DNA in human stool — Metagenomic Estimation of Dietary Intake (MEDI) — by examining faecal metagenomes. This new, semi-quantitative
-
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-07 Christopher D. Byrne, Angelo Armandi, Vanessa Pellegrinelli, Antonio Vidal-Puig, Elisabetta Bugianesi
Correction to: Nature Reviews Gastroenterology & Hepatology https://doi.org/10.1038/s41575-025-01045-z, published online 17 February 2025.
-
ECCO’25 Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-06 Eleni Kotsiliti
In February 2025, Nature Reviews Gastroenterology & Hepatology attended the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO’25) in Berlin, Germany. According to the organizers, 1,776 abstracts were submitted, of which 1,358 were posters and 176 were oral presentations. Compared with previous years, ECCO’25 had the highest attendance, with 8,156 delegates. This year, ECCO focused
-
Developing an adaptive platform trial for evaluation of medical treatments for Crohn’s disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-05 Nurulamin M. Noor, Shellie J. Radford, Babak Choodari-Oskooei, Morris Gordon, Ailsa L. Hart, Trish Hepburn, Ed Juszczak, James O. Lindsay, Nicholas A. Kennedy, Mahesh K. B. Parmar, Vipul Jairath, Gordon W. Moran
-
AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-03 Marietta Iacucci, Yasuharu Maeda, Giovanni Santacroce, Subrata Ghosh
-
A Consensus Statement on establishing causality, therapeutic applications and the use of preclinical models in microbiome research Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-03 Amira Metwaly, Aicha Kriaa, Zahra Hassani, Federica Carraturo, Celine Druart, Kaline Arnauts, Paul Wilmes, Jens Walter, Stephan Rosshart, Mahesh S. Desai, Joel Dore, Hervé M. Blottiere, Emmanuelle Maguin, Dirk Haller
-
Reframing obesity and MASLD Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-28
As the burden of obesity and metabolic dysfunction-associated steatotic liver disease increases, the focus is shifting to the wide spectrum of disease, more accurate diagnostic criteria and the systems that influence our health to advance care.
-
Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-26 Norbert Stefan, Giovanni Targher
-
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-26 Jonas Wizenty, Michael Sigal
-
Influence of biological sex in inflammatory bowel diseases Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-17 Diane M. Tshikudi, Charles N. Bernstein, Suresh Mishra, Jean-Eric Ghia, Heather K. Armstrong
-
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-17 Christopher D. Byrne, Angelo Armandi, Vanessa Pellegrinelli, Antonio Vidal-Puig, Elisabetta Bugianesi
-
Neuroimmune interactions influence pancreatic glucagon secretion in fasting mice Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-12 Jordan Hindson
In a new study published in Science, researchers identify a mechanism in mice by which the nervous and immune systems interact to regulate blood glucose levels by controlling pancreatic glucagon secretion. First, they observed that mice with no adaptive lymphocytes and innate lymphoid cells (ILCs) (Rag2−/−Il2rg−/−) had reduced blood glucose and glucagon levels during fasting. But this effect was not
-
Author Correction: Understanding the therapeutic toolkit for inflammatory bowel disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-10 Sophie Vieujean, Vipul Jairath, Laurent Peyrin-Biroulet, Marla Dubinsky, Marietta Iacucci, Fernando Magro, Silvio Danese
Correction to: Nature Reviews Gastroenterology & Hepatology https://doi.org/10.1038/s41575-024-01035-7, published online 31 January 2025.
-
Bridging the gap between science and survival Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-07 Ahsen Ustaoglu
A scientist’s personal journey through breast cancer underscores the urgency for greater empathy in research and healthcare, a patient-centred approach to data dissemination, and more comprehensive, streamlined support for early-career researchers navigating health crises.
-
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-05 Timothy M. Block, Ju-Tao Guo, Fabien Zoulim, Charles M. Rice, Chloe L. Thio, William M. Schneider, Harvey J. Alter, Ira M. Jacobson, Robert G. Gish, Peter D. Block, Mark Sulkowski, Jordan J. Feld, Chari A. Cohen
-
Is precision microbiome medicine just around the corner? Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-04 Silvia Turroni
A study in Nature Medicine developed a new clinical test based on a gut metagenome-derived multispecies biomarker panel for the diagnosis of inflammatory bowel disease, which outperformed faecal calprotectin. Shortly after, a study in Cell identified a health-relevant network-based core microbiome that could substantially advance precision microbiome medicine.
-
MASLD as a non-communicable disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-04 Silvia Sookoian, Carlos J. Pirola, Arun J. Sanyal
Non-communicable diseases represent the primary cause of mortality and morbidity globally, accounting for 74% of all deaths and more than three-quarters of years lived with disability. Here, we argue that metabolic dysfunction-associated steatotic liver disease should be considered a non-communicable disease.
-
Understanding the therapeutic toolkit for inflammatory bowel disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-31 Sophie Vieujean, Vipul Jairath, Laurent Peyrin-Biroulet, Marla Dubinsky, Marietta Iacucci, Fernando Magro, Silvio Danese
-
MASH-induced senescence and liver cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-28 Katrina Ray
Metabolic dysfunction-associated steatohepatitis (MASH) is known to increase the risk of hepatocellular carcinoma (HCC), yet also triggers hepatocyte senescence (a tumour-suppressive cell state). New research shows that the gluconeogenic enzyme fructose-1,6-bisphophatase (FBP1) serves as a key control point in the switch from MASH to HCC. “Since senescence describes a non-dividing cell state associated
-
Coeliac disease: complications and comorbidities Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-28 Jonas F. Ludvigsson, Jialu Yao, Benjamin Lebwohl, Peter H. R. Green, Shuai Yuan, Daniel A. Leffler
-
Rome Foundation Working Team Report on overlap in disorders of gut–brain interaction Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-27 Giovanni Barbara, Imran Aziz, Sarah Ballou, Lin Chang, Alexander C. Ford, Shin Fukudo, Samuel Nurko, Carolina Olano, Miguel Saps, Gregory Sayuk, Kewin T. H. Siah, Lukas Van Oudenhove, Magnus Simrén
-
Preventing the progression of cirrhosis to decompensation and death Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-27 Càndid Villanueva, Dhiraj Tripathi, Jaume Bosch
-
Drug approvals in gastroenterology and hepatology in 2024 Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-13 Eleni Kotsiliti
2024 saw the approvals of several drugs by the FDA and the EMA related to gastroenterology and hepatology. In 2024, the FDA also approved biosimilar products to Stelara (Janssen; ustekinumab, a monoclonal antibody targeting IL-12 and IL-23) for the treatment of moderate to severely active Crohn’s disease and ulcerative colitis, which included Steqeyma (Celltrion), Yesintek (Biocon Biologics), Imuldosa
-
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-02 Yasser Fouad, Salma Barakat, Almoutaz Hashim, Hasmik Ghazinyan
Correction to: Nature Reviews Gastroenterology & Hepatology https://doi.org/10.1038/s41575-024-00918-z, published online 18 March 2024.